secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2026-11-04T21:58:47+00:00
Accession:  0001193125-26-447550
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Rallybio holders approve Avenzo merger and $13.90/share cash distribution; close expected Nov. 6
--------------------------------------------------------------------------------

- All eight annual-meeting proposals passed; Proposal 1, issuing Rallybio stock to Avenzo holders (>20% and a change of control), won 4,506,703 for vs 15,979 against.
- Special cash distribution set at $83.6 million, or $13.90 per share, to holders of record Nov. 5, 2026; transfer agent payment expected Nov. 13, 2026.
- Stock trades with due bills Nov. 5-6, 2026 ahead of the Nov. 9 ex-dividend date; investors must hold through the Nov. 6 close to receive the distribution.
- Merger expected to close Nov. 6, 2026; Rallybio will be renamed Avenzo Therapeutics, raise authorized shares to 500M from 200M, with a 1-for-2 to 1-for-9 reverse split not done pre-close.
- Avenzo 2026 Equity Incentive Plan reserve equals 18% of post-merger shares outstanding; 2026 ESPP reserve 1%, each with annual evergreen increases through 2036.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526447550/0001193125-26-447550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526447550/d164725d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-447550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer